Literature DB >> 18086245

Understanding signaling cascades in melanoma.

Pablo Lopez-Bergami1, Boris Fitchman, Ze'ev Ronai.   

Abstract

Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control, metabolism, motility and the ability to escape cell death programs. Here we review the major signaling pathways currently known to be deregulated in melanoma with an implication to its development and progression. Among these pathways are Ras, B-Raf, MEK, PTEN, phosphatidylinositol-3 kinase (PI3Ks) and Akt which are constitutively activated in a significant number of melanoma tumors, in most cases due to genomic change. Other pathways discussed in this review include the [Janus kinase/signal transducer and activator of transcription (JAK/STAT), transforming growth factor-beta pathways which are also activated in melanoma, although the underlying mechanism is not yet clear. As a paradigm for remodeled signaling pathways, melanoma also offers a unique opportunity for targeted drug development.

Entities:  

Mesh:

Year:  2007        PMID: 18086245      PMCID: PMC2874067          DOI: 10.1111/j.1751-1097.2007.00254.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  286 in total

Review 1.  A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling.

Authors:  Michael T Veeman; Jeffrey D Axelrod; Randall T Moon
Journal:  Dev Cell       Date:  2003-09       Impact factor: 12.270

2.  PI3-kinase subunits are infrequent somatic targets in melanoma.

Authors:  John A Curtin; Mitchell S Stark; Daniel Pinkel; Nicholas K Hayward; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2006-04-13       Impact factor: 8.551

3.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

4.  Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.

Authors:  K V Bhatt; R Hu; L S Spofford; A E Aplin
Journal:  Oncogene       Date:  2006-08-21       Impact factor: 9.867

Review 5.  Genetic alterations in signaling pathways in melanoma.

Authors:  Frank G Haluska; Hensin Tsao; Helen Wu; Frank S Haluska; Alexander Lazar; Vikas Goel
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors:  P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

7.  Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome.

Authors:  Eric Kielhorn; Elayne Provost; Drew Olsen; Thomas G D'Aquila; Bradley L Smith; Robert L Camp; David L Rimm
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

8.  Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia.

Authors:  A H Parmiter; G Balaban; W H Clark; P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1988-02

9.  Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome.

Authors:  Ashani T Weeraratna; Dorothea Becker; Kristen M Carr; Paul H Duray; Kevin P Rosenblatt; Sherry Yang; Yidong Chen; Michael Bittner; Robert L Strausberg; Gregory J Riggins; Urs Wagner; Olli P Kallioniemi; Jeffrey M Trent; Patrice J Morin; Paul S Meltzer
Journal:  Oncogene       Date:  2004-03-18       Impact factor: 9.867

10.  Transcription factor ATF2 cooperates with v-Jun to promote growth factor-independent proliferation in vitro and tumor formation in vivo.

Authors:  S Huguier; J Baguet; S Perez; H van Dam; M Castellazzi
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  35 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

2.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

3.  The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.

Authors:  Nai-Ying Yang; Pablo Lopez-Bergami; James S Goydos; Dana Yip; Ameae M Walker; Elena B Pasquale; Iryna M Ethell
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-23       Impact factor: 4.693

Review 4.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

5.  MicroRNA in Melanoma.

Authors:  Paul M Howell; Xiaobo Li; Adam I Riker; Yaguang Xi
Journal:  Ochsner J       Date:  2010

6.  Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention.

Authors:  Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Alina Lipavsky; Jules Gadiot; Christian Blank; Richard Eb Seftor; Elisabeth A Seftor; Mary Jc Hendrix
Journal:  Expert Rev Dermatol       Date:  2009

Review 7.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis.

Authors:  Meera Shah; John L Stebbins; Antimone Dewing; Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-27       Impact factor: 4.693

Review 10.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.